Drugs / BBI-825
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06299761 | Mar 2024 → Jun 2025 | cancer | Boundless Bio, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05827614 | Mar 2023 → Mar 2026 | cervical squamous cell carcinoma, endometrial carcinoma, estrogen-receptor positive breast cancer, head and neck squamous cell carcinoma +7 | Boundless Bio, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-13 | Boundless Bio, Inc. | Results Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics boundlessbio.com ↗
BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBI-825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299761 ↗ |
| Action | Inhibit | “Oral RNR Inhibitor” NCT05827614 ↗ |
| Modality | Small molecule | “BBI-825 is an oral, potent, selective ribonucleotide reductase (or RNR) small molecule inhibitor.” NCT05827614 ↗ |
| Route | Oral | “Combination therapy of BBI-355 and RNR Inhibitor BBI-825, administered orally in 28-day cycles.” NCT05827614 ↗ |